Filter Results
Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma
The evaluation of bone disease in multiple myeloma (MM) is an important topic in imaging. This study retrospectively investigated whole-body diffusion-weighted imaging (WB-DWI) in the evaluation of bone marrow infiltration and treatment response in MM.
IgA nephropathy in IgG kappa multiple myeloma
Multiple myeloma (MM) frequently affects kidney function through multiple mechanisms. Nonetheless, some patients develop kidney injury due to other causes.
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?
Multiple myeloma is a disease of elderly adults. Improvement in survival has occurred because of biological insights and novel agents. Therapeutic options involve choices today, thus have become more complex. Demographics have led to an increased number of elderly patients and age may be associated with a poorer outcome but is not the only prognostic predictor today.
Digital Health for Patients With Multiple Myeloma: An Unmet Need
Multiple myeloma (MM) is associated with the highest symptom burden and lowest health-related quality of life (HRQoL) among patients with hematologic malignancies. HRQoL in MM is heterogeneous, varying over the course of disease, with the highest burden at diagnosis and relapse. Patients with MM are increasingly being treated with oral maintenance medications at home
First-in-Human Clinical Trial Results for Novel CELMoD CC-92480
To date, there remains no cure for multiple myeloma, despite numerous advances in treatment over the last 20 years.
Initial Results From the Phase III BOSTON Study for Multiple Myeloma
Selinexor, the orally bioavailable first-in-class selective inhibitor of nuclear export (SINE) was initially approved by the FDA in July 2019 in combination with dexamethasone for previously treated patients with relapsed or refractory multiple myeloma.
Encouraging Findings for Belantamab Mafodotin in Treating Multiple Myeloma
Belantamab mafodotin is an immunoconjugate targeting B-cell maturation antigen, a pathway shown to be important for the growth and survival of myeloma cells.
Immune System Changes Can Impact Development of Multiple Myeloma
For the last 4-5 years, Irene Ghobrial, MD, and researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital have focused their efforts on trying to understand mechanisms of disease progression from early precursor conditions, like monoclonal gammopathy of unknown significance (MGUS), to myeloma.